Corresponding Author: Wojciech K. Mydlarz, MD, Department of Otolaryngology–Head and Neck Surgery, Johns Hopkins University School of Medicine, JHOC 6210, 601 N Caroline St, Baltimore, MD 21287 (email@example.com).
Published Online: February 2, 2023. doi:10.1001/jamaoto.2022.4828
Conflict of Interest Disclosures: Dr Toni reported involvement with a Medical Research Scholars Program fellowship from the National Institutes of Health (NIH) during the submitted work. No other disclosures were reported.
Additional Contributions: We thank Chyi-Chia Richard Lee, MD, PhD, for his evaluation of the pathology specimen and critical review of the manuscript. This individual was not compensated for their contributions. We also thank the patient for granting permission to publish this information.
Additional Information: This research was made possible through the NIH Medical Research Scholars Program, a public-private partnership supported jointly by the NIH and contributions to the Foundation for the NIH from the Doris Duke Charitable Foundation, the American Association for Dental Research, the Colgate-Palmolive Company, and other private donors. For a complete list, please visit the Foundation website at http://fnih.org/what-we-do/current-education-and-training-programs/mrsp.
JM , Friedman
J , Robbins
et al. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer. J Clin Invest
. 2022;132(18):e161400. doi:10.1172/JCI161400Google ScholarCrossref
Merck Sharp & Dohme LLC. Study of pembrolizumab given prior to surgery and in combination with radiotherapy given post-surgery for advanced head and neck squamous cell carcinoma (MK-3475-689). Updated December 2022. https://clinicaltrials.gov/ct2/show/NCT03765918